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Background: Androgen receptor (AR) signalling is critical to the initiation and progression of prostate cancer (PCa).
Transcriptional activity of AR involves chromatin recruitment of co-activators, including the p300/CBP-associated
factor (PCAF). Distinct miRNA expression profiles have been identified in PCa cells during the development and
progression of the disease. Whether miRNAs regulate PCAF expression in PCa cells to regulate AR transcriptional
activity is still unclear.
Methods: Expression of PCAF was investigated in several PCa cell lines by qRT-PCR, Western blot, and
immunocytochemistry. The effects of PCAF expression on AR-regulated transcriptional activity and cell growth in
PCa cells were determined by chromatin immunoprecipitation, reporter gene construct analysis, and MTS assay.
Targeting of PCAF by miR-17-5p was evaluated using the luciferase reporter assay.
Results: PCAF was upregulated in several PCa cell lines. Upregulation of PCAF promoted AR transcriptional
activation and cell growth in cultured PCa cells. Expression of PCAF in PCa cells was associated with the
downregulation of miR-17-5p. Targeting of the 3’-untranslated region of PCAF mRNA by miR-17-5p caused
translational suppression and RNA degradation, and, consequently, modulation of AR transcriptional activity in PCa
cells.
Conclusions: PCAF is upregulated in cultured PCa cells, and upregulation of PCAF is associated with the
downregulation of miR-17-5p. Targeting of PCAF by miR-17-5p modulates AR transcriptional activity and cell
growth in cultured PCa cells.Background
Prostate cancer (PCa) represents one of the most fre-
quently diagnosed malignancies in men worldwide [1].
The androgen receptor (AR) is a member of the nuclear
receptor superfamily that regulates ligand-dependent
gene transcription [2]. Upon androgen binding, AR
translocates to the nucleus and binds to consensus
sequences of androgen response elements (AREs) in the
genome to activate genes, such as prostate-specific anti-
gen (PSA) [2,3]. Many of these AR-regulated genes are
key regulators of prostate development and mainte-
nance. AR signalling is also critical to the initiation and* Correspondence: xianmingchen@creighton.edu
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reproduction in any medium, provided the orprogression of PCa, and androgen-deprivation therapy
remains the most prevalent treatment [2-4].
Growing evidence has shown that co-regulators, factors
recruited by transcription factors to activate or repress
transcription, are indispensable components of transcrip-
tional gene regulation [5]. Under physiological conditions,
co-activators are necessary for the formation of a product-
ive transcriptional AR complex by facilitating DNA occu-
pancy, chromatin remodeling, and/or AR protein stability
and acetylation [4]. Amplification or overexpression of AR
and its co-activators can sensitize cells toward a low level
of androgen and has been postulated to account for aber-
rant AR activation in PCa [4]. In the progression of PCa, a
subset of co-repressors is downexpressed [4]. Therefore,
aberrant expression of co-regulators for AR may contri-
bute to promiscuous activation of AR signaling in PCatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shown to act as a co-activator to regulate gene tran-
scription, potentially including AR-regulated transcrip-
tional activity in PCa cells [6,7]. PCAF possesses histone
acetyltransferase (HAT) activity, by which it renders the
chromatin environment more easily accessible for the
transcriptional machinery. Apart from the acetylation of
histones, HATs have been shown to acetylate AR, promo-
ting AR transcriptional activity [5]. Nevertheless, expres-
sion of PCAF in PCa cells and its potential significance in
PCa disease progression has not been fully elucidated.
MicroRNAs (miRNAs) are small, non-coding RNAs
that regulate posttranscriptional gene expression based
on the complementarity between miRNAs and target
mRNAs. This causes either mRNA cleavage and/or
translational suppression, resulting in gene suppression
[8]. To date, more than 1,000 human miRNAs have been
identified and, as predicted, control the expression of ap-
proximately 60% of human genes [9]. miRNAs are differ-
entially expressed in normal and tumor cells, as well as
between tumor subtypes [10,11]. Pathologically, miRNAs
can be involved in the deregulation of the expression of
important genes that play key roles in tumorigenesis,
tumor development, and angiogenesis and have onco-
genic or tumor suppressor roles [10,11]. The potential
for use of miRNAs as biomarkers and therapeutic targets
against cancer has been extensively studied [12,13]. Such
approaches to manipulate the expression of miRNA tar-
gets in the context of disease are currently being
explored in clinical trials [12]. Clinically, miRNA expres-
sion becomes altered with the development and progres-
sion of PCa [14]. Some of these miRNAs have been
demonstrated to regulate the expression of cancer-
related genes in PCa cells [15]. Ectopic expression of
these miRNAs significantly reduced PCa growth, sug-
gesting growth modulatory roles for these miRNAs in
PCa cells [16]. A recent report demonstrates that miR-
17 may target PCAF in HeLa cells [17]. Interestingly,
several miRNA arrays done by different laboratories
revealed an aberrant expression of miR-17 in PCa cells
[18-20]. The pathogenic significance of aberrant expres-
sion of miR-17 in PCa cells is still unclear.
In this study, we investigated the expression of PCAF
in PCa cells, its targeting by miR-17-5p, and its potential
effects on AR transcriptional activity. The data demon-
strate that PCAF is a target for miR-17-5p in PCa cells.
Downregulation of miR-17-5p causes overexpression of
PCAF in human PCa cells, promoting AR transcriptional
activity and PCa cell growth.
Methods
Cell lines and reagents
RWPE1 (non-malignant prostate epithelial cells) and
LNCaP, C4-2B, and PC3 PCa cells were cultured andmaintained as previously reported [17-20]. PrEC (normal
human prostate epithelial cells) were obtained from
ATCC. The pCX-PCAF (Flag-tagged) was a gift from
Dr. Tony Kouzarides (University of Cambridge, UK).
PCAF siRNA was from Santa Cruz. 4, 5 α-dihydrotestos-
terone (DHT) (Sigma-Aldrich) was used at 10 nM, as
indicated in each experiment. DHT was dissolved in
ethanol, which was also used as the control vehicle.
Western blot
Whole cell lysates were obtained from cells with M-PER
Mammalian Protein Extraction Reagent (Thermo Scien-
tific) plus several protease inhibitors (1 mM PMSF;
10 μg/mL leupeptin, 2 μg/mL pepstatin). Cell lysates
were then loaded at each line (a total of 40 μg lysate pro-
teins) in 4-12% SDS page gel to separate proteins and
transferred to nitrocellulose membrane. Antibodies to
PCAF (SC13124, Santa Cruz, at a final concentration of
1 μg/ml) and β-actin (A2668, Sigma-Aldrich) were used.
Densitometric levels of PCAF signals were quantified
and expressed as their ratio to β-actin.
Immunocytochemistry
For immunocytochemistry staining, cells were fixed with
2% paraformaldehyde and incubated with a monoclonal
antibody against PCAF (Santa Cruz, at a final concentra-
tion of 4 μg/ml), followed by anti-rabbit FITC-conju-
gated secondary antibody (Invitrogen) and co-staining
with 4’, 6-diamidino-2-phenylindole (DAPI, 1.5 μg/ml) to
stain cell nuclei. Labelled cells were assessed by fluores-
cence microscopy.
Quantitative real-time PCR (qRT-PCR)
Comparative qRT-PCR was performed using the SYBR
Green PCR Master Mix (Applied Biosystems). The PCR
primers as follows: PCAF, forward (50-CTGGAGGCAC
CATCTCAACGAA-30) and reverse (50-ACAGTGAAGA
CCGAGCGAAGCA-30); PSA, forward (50-ACCAGAG
GAGTTCTTGACCCCAAA-30) and reverse (50-CCCCA
GAATCACCCGAGCAG-30); and GAPDH, forward (50-
TGCACCACCAACTGCTTAGC-30) and reverse (50-
GGCATGGACTGTGGTCATGAG-30). Total RNA was
isolated from cells with Trizol reagent (Ambion) and trea-
ted with DNA-free Kit (Ambion) to remove any remaining
DNA. qRT-PCR was performed in triplicate on the Ap-
plied Biosystems 7500 FAST Real-time PCR System. The
Ct values were analyzed using the comparative Ct (ΔΔCt)
method, and the target amount was obtained by normaliz-
ing to the endogenous reference (GAPDH) and relative to
the control (untreated cell) [21,22]. For PCR analysis of
mature miR-17-5p, total RNAs were extracted using the
mirVana miRNA Isolation kit (Ambion). Hsa-miR-17-5p
and snRNA RNU6B PCR primer sets were obtained from
Applied Biosystems. Comparative qRT-PCR was
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Master Mix (Applied Biosystems). Mature miR-17-5p ex-
pression level was obtained by normalizing to the en-
dogenous reference (snRNA RNU6B) and relative to the
control (untreated cell) [21,22].
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed with a commercially avail-
able ChIP Assay Kit (Upstate Biotechnologies) in accord-
ance with the manufacturer’s instructions. In brief, 1 × 106
cells cultured in 10 cm culture dishes were cultured in the
presence or absence of DHT (10 nM) for 5 h. The chro-
matin fraction was immunoprecipitated overnight at 4°C
using anti-PCAF (Santa Cruz, at a final concentration of
2 μg/ml) or anti-AR (Santa Cruz, 2 μg/ml). A non-specific
IgG (Santa Cruz) was used for control. Semi-quantitative
PCR was performed with 1 μl of DNA using GoTaq Color-
less Master Mix (Promega). PCR products were run in 1%
Agarose gel. Densitometric levels were quantified and
expressed as a ratio to the input. The primers used for the
ARE-I region of the PSA promoter were forward (50-
TCTGCCTTTGTCCCCTAGAT-30) and reverse (50-
AACCTTCATTCCCCAGGACT-30) [23]. Primers cover-
ing the following non-ARE region of the PSA promoter
were used for control: forward (50-CTGTGCTTGGAGTT
TACCTG A-30) and reverse (50-GCAGAGGTTGCAGT
GAGCC-30) [23].
Anti-miR-17-5p and miR-17-5p precursor
Anti-miR-17-5p (Applied Biosystems) was used to inhibit
miR-17-5p function and specific miR-17-5p precursor
(pre-miR-17-5p, Applied Biosystems) to increase miR-17-
5p expression [24]. Anti-miRs (anti-miR miRNA inhibi-
tors) are commercially available, chemically modified
single-stranded nucleic acids designed to specifically bind
to and inhibit function of endogenous miRNAs [24]. For
experiments, cells were grown to 70% confluent and trea-
ted with anti-miR or precursor to miR-17-5p (0-30 nM,
Ambion) using the lipofectamine 2000 reagent (Invitro-
gen). Non-specific anti-miR (anti-miR-Ctrl) and precursor
(precursor-Ctrl) (Ambion) were used as controls.
Luciferase reporter constructs with PCAF 3’UTR and
luciferase assay
Complementary 38 bp DNA oligonucleotides containing
the putative miR-17-5p target site within the 30-
untranslated region (30UTR) of human PCAF were
synthesized with flanking SpeI and HindIII restriction en-
zyme digestion sites (Sense, 50-CTAGGACTTGTAAATG
TAATAATTAGCACTTTTGAAAA-30; antisense, 50-
AGCTTTTTCAAAAGTGCTAATTATTACATTTACAA
GTC-30) and cloned into the multiple cloning site of the
pMIR-REPORT Luciferase vector (Ambion). pMIR-
REPORT Luciferase constructs containing mutant 3’UTR(ACTTT to AGAAT) were also generated. We then trans-
fected cultured cells with each reporter construct (250 ng/
well in a 24-well plant) and the internal pMIR-REPORT
β-gal control construct (Ambion, 250 ng/well), as well as
anti-miR-17-5p or precursor to miR-17-5p using the Lipo-
fectamine 2000 reagent (Invitrogen). Luciferase activity
was measured and normalized to the control β-gal level as
previously reported [21,22].
PSA luciferase reporter assay
Transfections were performed using the Lipofectamine
2000 reagent (Invitrogen). Briefly, cells (1x105 cells/well)
were seeded in 24-well plates. When cells grew to 70–
80% confluence, 250 ng of the pGL3-PSA-6 kb luciferase
reporter construct [25] and 100 ng of CMV-β-gal were
transfected. After 6 h incubation, the medium was chan-
ged to the RPMI medium with 1% charcoal stripped fetal
bovine serum (Life Technologies) overnight and then
exposed to DHT for 24 h. Luciferase activity was mea-
sured and normalized with the β-gal.
Cell growth
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2 H tetrazolium (MTS) assay
was used to detect cell growth. The nonradioactive cell
proliferation MTS Assay Kit was from Promega (Pro-
mega, WI). Cells were cultured in 24-well plates at a
density of 5x104 cells per well for 72 h. For measure-
ment, 25 μL of MTS reagent was added to the medium
and cells were incubated at 37°C for 1 h. The absorbance
was read at 490 nm in 200 μL of soluble formazan
medium with a microplate spectrophotometer. Cell
number was then calculated from a standard cure and
expressed as percentage of the control.
Statistical analysis
Values are given as mean ± SE. Significance was exam-
ined by unpaired Student’s t-test. p < 0.05 was considered
statistically significant.
Results
PCAF is upregulated in human PCa cell lines
We first measured the PCAF expression levels by West-
ern blot and qRT-PCR in several human PCa cell lines.
As shown in Figure 1A and 1B, a significant increase of
PCAF protein content was detected in these PCa cell
lines, compared with two human prostate epithelial cell
lines (i.e., RWPE1 and PrEC). A significant increase in
PCAF mRNA levels was also found in PCa cells as
assessed by qRT-PCR (Figure 1B). Increased expression
of PCAF in LNCaP cells was further confirmed by im-
munofluorescent staining using an antibody to PCAF
(Figure 1C and 1D).
Figure 1 Expression of PCAF in cultured cell lines. A and B, expression of PCAF as assessed by Western blot and qRT-PCR, respectively.
Representative Western blots are shown in A; β-actin was also blotted to ensure equal loading. The amount of PCAF mRNA is shown in B. Data in
B are averages of three independent experiments. *, p < 0.05 compared to RWPE1 and PrEC cells. C and D, expression of PCAF protein in RWPE1
and LNCaP cells as assessed by immunofluorescent staining. PCAF was stained in green using a specific anti-PCAF antibody (in D). Cell nuclei
were stained in blue with DAPI and overlaid images were also shown. The non-specific IgG was used as the control (as shown in C). Bar = 10 μm.
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DHT-stimulated AR transcriptional activity and cell
growth in LNCaP cells
To investigate the impact of PCAF overexpression on
AR signalling in PCa cells, we used AR-responsive
LNCaP cells to test the effects of functional manipula-
tion of PCAF on DHT-induced AR transcriptional acti-
vity and cell growth. Forced expression of PCAF was
carried out through transfection of cells with the pCX-
PCAF construct, and a siRNA to PCAF was used to
knock down PCAF expression, as shown in Figure 2A.
Treatment of LNCaP cells with the PCAF siRNA attenu-
ated DHT-induced expression of PSA as assessed by
qRT-PCR (Figure 2B). In contrast, transfection of
LNCaP cells with the pCX-PCAF caused a two-fold in-
crease in DHT-induced expression of PSA gene
(Figure 2B). In addition, we took a well-documented
PSA 6 kb-promoter luciferase reporter assay [25,26] and
tested the impact of PCAF on DHT-induced AR activity.
Consistent with data from previous studies [27], DHT
increased AR-associated PSA luciferase activation inLNCaP cells (Figure 2C and 2D). Transfection of cells
with the pCX-PCAF enhanced DHT-induced PSA luci-
ferase activity (Figure 2C). Complementarily, knockdown
of PCAF by the PCAF siRNA partially abolished DHT-
induced PSA luciferase activity (Figure 2D). Cells
transfected with the empty vector or treated with the
non-specific scrambled siRNA showed no changes in
DHT-induced PSA luciferase activity, and pCX-PCAF and
PCAF siRNA displayed a similar effect on DHT-induced
PSA expression in C4-2B cells as in LNCaP cells (data not
shown). Consistent with results from previous studies
[27], DHT stimulated LNCaP cell growth (Figure 2E).
Transfection of cells with the pCX-PCAF construct pro-
moted DHT-induced cell growth (Figure 2E). In contrast,
knockdown of PCAF through siRNA significantly
decreased DHT-induced cell growth (Figure 2F).
To explore the possible mechanisms underlying
PCAF-mediated AR transcriptional activation, we tested
the promoter recruitment of PCAF to the AR-regulated
PSA gene following DHT stimulation by ChIP analysis.
AREs were previously identified in the promoter region
Figure 2 (See legend on next page.)
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Figure 2 PCAF is a co-activator to AR and promotes DHT-induced AR transcriptional activity and cell growth. A, knockdown of PCAF by
siRNA and forced expression of PCAF through transfection of the pCX-PCAF in LNCaP cells, as confirmed by Western blot and PCR analysis.
B, functional manipulation of PCAF on DHT-induced transcription of PSA in LNCaP cells. Cells were exposed to DHT (10 nM) for up to 48 h,
followed by qRT-PCR. DHT was also used to stimulate LNCaP cells that were pre-treated with siRNA to PCAF or transfected with the pCX-PCAF for
24 h. C and D, functional manipulation of PCAF on DHT-induced PSA-6 kb luciferase activity in LNCaP cells. Cells were transfected with the PSA-6 kb
luciferase reporter plasmid with PCAF siRNA or pCX-PCAF for 24 h, then exposed to DHT (10 nM) for 24 h. Luciferase activity was measured and
presented as the ratio to β-gal. E and F, functional manipulation of PCAF on DHT-stimulated LNCaP cell growth. Cells were transfected with
pCX-PCAF (E) or treated with PCAF siRNA (F) for 24 h and then exposed to DHT (10 nM) for 72 h, followed by MTS assay. G and H, ChIP analysis
of DHT-induced promoter recruitment AR and PCAF to the ARE region of the PSA gene in LNCaP cells. Cells were exposed to DHT (10 nM) for
5 h and immunoprecipitated with antibodies to AR or PCAF, or the IgG control. Specific PCR primers covering the ARE-I region of the PSA
promoter were used for the PCR analysis and data were presented as ratio to the input. Data in A to F are averages of three independent
experiments. *, p < 0.05 compared to non-DHT treated cells (in B, C, D, E, F and H) or siRNA control (in A). #, p < 0.05 compared to cells treated
with DHT only. Luc = luciferase activity.
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of primers for the ChIP analysis: one set of primers co-
vers the corresponding ARE-I in the promoter of the
PSA gene and the other set of primers covers the non-
ARE region as the control [23]. Increased promoter re-
cruitment of AR and PCAF to the ARE region in the
PSA promoter was detected in LNCaP cells following
DHT stimulation (Figure 2G and 2H), whereas no bind-
ing of AR and PCAF was detected in the non-ARE re-
gion (data not shown).
PCAF is a target for miR-17-5p in cultured PCa cells
Significant complementarity between PCAF 3’UTR and
miR-17-5p has been identified in previous studies [17]. To
correlate expression of miR-17-5p to PCAF upregulation
in PCa cells, we generated a luciferase construct that con-
tains the potential binding sequence of PCAF 3’UTR to
miR-17-5p (Figure 3A). RWPE1 and LNCaP cells were
then transfected with this construct, and luciferase activity
was measured 24 h after transfection. Luciferase activity
was significantly decreased in cells transfected with the
PCAF 3’UTR construct with the potential binding site,
compared with cells transfected with the empty control
vector or the mutant 3’UTR mutant (ACTTT to AGAAT
at the putative binding site), suggesting endogenous trans-
lational repression of the construct with the PCAF 3’UTR.
A stronger inhibitory ratio of luciferase activity was
observed in RWPE1 cells than LNCaP cells. In addition,
anti-miR-17-5p markedly increased PCAF 3’UTR-
associated luciferase reporter translation. In contrast, miR-
17-5p precursor significantly decreased luciferase reporter
translation (Figure 3B). Interestingly, a lower level of ma-
ture miR-17-5p content was detected in multiple PCa cell
lines, compared with the RWPE1 and PrEC cells
(Figure 3C). To test whether miR-17-5p-mediated sup-
pression of PCAF is directly relevant to PCAF expression
in prostate epithelial cells, we treated cells with miR-17-5p
precursor or anti-miR-17-5p and then measured PCAF
protein level (treated for 48 h) by Western blot or mRNA
level (treated for 24 h) by qRT-PCR. Transfection ofLNCaP cells with the miR-17-5p precursor caused a sig-
nificant decrease in PCAF protein content (Figure 3D)
and PCAF mRNA level (Figure 3E). Conversely, an in-
crease in PCAF protein level and message level was
detected in RWPE1 and LNCaP cells after treatment with
the anti-miR-17-5p (Figure 3F and 3G).
miR-17-5p modulates DHT-induced AR transcriptional
activity and cell growth in cultured PCa cells
Since PCAF is a target of miR-17-5p, manipulation of
miR-17-5p function should influence AR transcriptional
activity and cell growth in PCa cells. Thus, we tested the
effects of anti-miR-17-5p or miR-17-5p precursor on
DHT-stimulated AR transcriptional activation using AR-
responsive LNCaP and C4-2B cells. Treatment of
LNCaP cells with anti-miR-17-5p significantly increased
DHT-induced expression of PSA, as assessed by qRT-
PCR (Figure 4A). In contrast, miR-17-5p precursor atte-
nuated DHT-induced expression of the PSA gene
(Figure 4B). Complementarily, effects of anti-miR-17-5p
and miR-17-5p precursor on DHT-stimulated AR acti-
vity were confirmed in LNCaP cells using the PSA 6 kb-
promoter luciferase assay (Figure 4C and 4D). Similar
results of anti-miR-17-5p or miR-17-5p precursor on
DHT-stimulated PSA 6 kb-promoter luciferase activity
were obtained in C4-2B cells (Figure 4E and 4F). More-
over, precursor to miR-17-5p inhibited DHT-induced
LNCaP cell growth (Figure 4G).
Discussion
The results of our study provide the first evidence, to
our knowledge, that miR-17-5p targets PCAF in PCa
cells and modulates AR-regulated transcriptional activity
and PCa growth. We found that PCAF is upregulated in
human PCa cells and acts as a co-activator to AR and
promotes DHT-stimulated AR transcriptional activity
and PCa cell growth. Importantly, PCAF is a target for
miR-17-5p, and upregulation of PCAF in PCa cells is
associated with the downregulation of miR-17-5p. These
data suggest that aberrant expression of miR-17-5p may
Figure 3 miR-17-5p targets PCAF 3’UTR, resulting in translational suppression and RNA degradation. A, the schematic of human PCAF
mRNA showed a potential binding site in its 3’UTR for miR-17-5p. The complementary miR-17-5p-binding site in the PCAF 3’UTR was inserted to
the downstream of a luciferase reporter on the pMIR-REPORT plasmid. A control plasmid with the mutant 3’UTR sequence was also generated.
WT = wild-type. B, binding of miR-17-5p to the potential binding site in the PCAF 3’UTR results in translational suppression, as assessed by
luciferase reporter assay. LNCaP and RWPE1 cells were transfected with the plasmids and treated with the anti-miR or precursor to miR-17-5p, or
non-specific oligo control, for 24 h, followed by luciferase analysis. Mut = mutant; *, p < 0.05 compared to the controls; #, p < 0.05 compared to
PCAF 3’UTR transfected alone. C, expression of miR-17-5p in cells, as assessed by qRT-CR. Mature miR-17-5p level was obtained by normalizing to
the endogenous reference RNU6B. D and E, miR-17-5p precursor decreases PCAF expression in LNCaP cells. Cells were treated with various doses
of miR-17-5p precursor or nonspecific precursor control, followed by Western blot for PCAF protein (after incubation for 48 h) or PCR for PCAF
mRNA (after incubation for 24 h). F and G, anti-miR-17-5p increases PCAF expression in RWPE1 and LNCaP cells. Cells were treated with various
doses of anti-miR-17-5p or non-specific anti-miR control followed by Western blot for PCAF protein (48 h) or PCR for PCAF mRNA (24 h). Data in
B, C, E, and G are averages of three independent experiments. *, p < 0.05 compared to RWPE1 and PrEC cells (in C) or the controls in E and G.
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PCa cells through modulation of PCAF expression at the
posttranscriptional level.
Transcriptional activity of the AR is regulated by co-
regulators, and the current study demonstrates that
ligand-induced AR function is enhanced by PCAF in
PCa cells. We found that PCAF was upregulated, both atthe protein and message levels, in several PCa cell lines.
The results of our luciferase reporter assay and ChIP
analysis further confirmed the involvement of PCAF in
the transcriptional regulation of AR-regulated PSA in
cultured PCa cells, including LNCaP cells and C4-2B
cells. Consequently, functional manipulation of PCAF
altered ligand-induced PCa cell growth. Our data
Figure 4 (See legend on next page.)
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expression, consistent with the results from previous
studies [28,29]. Of note, it appears that both androgen-
sensitive (LNCaP) and androgen-refractory (C4-2B andPC-3) cell lines showed an increase in PCAF expression.
Therefore, upregulation of PCAF may not be a critical
determinant for the hormone-refractory or castration-
resistant emergence of the disease. Interestingly,
(See figure on previous page.)
Figure 4 Effects of functional manipulation of miR-17-5p on DHT-induced AR transcriptional activity and cell growth. A and B, impact of
functional manipulation of miR-17-5p on DHT-induced transcription of the PSA gene. LNCaP cells were treated with anti-miR-17-5p or miR-17-5p
precursor for 48 h and then exposed to DHT (10 nM) for an additional 24 h, followed by qRT-PCR analysis. C - F, impact of functional
manipulation of miR-17-5p on DHT-induced PSA-6 kb luciferase activity in LNCaP cells (C and D) and C4-2B cells (E and F). Cells were transfected
with the PSA-6 kb luciferase reporter plasmid and simultaneously treated with anti-miR-17-5p or miR-17-5p precursor for 48 h, then exposed to
DHT (10 nM) for an additional 24 h. Luciferase activity was measured and presented as the ratio to β-gal. G, inhibition of miR-17-5p precursor on
DHT-stimulated LNCaP cell growth. Cells were treated with miR-17-5p precursor for 48 h then exposed to DHT (10 nM) for 72 h, followed by MTS
assay. Data are averages of three independent experiments. *, p < 0.05 compared to non-DHT-treated cells (in A -G); #, p < 0.05 compared to cells
treated with DHT only. Luc = luciferase activity.
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growth in the absence of DHT. One possible explanation
for this observation is that forced expression of pCX-
PCAF may also stimulate cell growth through AR-
independent mechanisms.
Whereas increased transcription of the PCAF gene
may be one of the mechanisms accounting for PCAF
upregulation in PCa cells, our data support that miRNA-
mediated posttranscriptional suppression may be
involved. In a recent report by Triboulet [17], miR-17-5p
was shown to bind to PCAF 3’UTR to suppress transla-
tion, resulting in suppression of the PCAF gene at the
posttranscriptional level in HeLa cells. Here, we con-
firmed the targeting of PCAF 3’UTR by miR-17-5p using
the luciferase reporter construct with the potential bind-
ing site for miR-17-5p in non-malignant prostate epithe-
lial cells and PCa cells. A significant decrease in the
luciferase reporter translation was detected in cells
transfected with miR-17-5p precursor, using the lucifer-
ase reporter construct covering the potential binding site
for miR-17-5p within PCAF 3’UTR. Meanwhile, we
found that LNCaP cells, after transfection of the miR-
17-5p precursor, also showed a decreased level of PCAF
mRNA. In contrast, treatment of RWPE1 and LNCaP
cells with anti-miR-17-5p increased PCAF mRNA level.
Therefore, both translational repression and induction of
RNA degradation are involved in miR-17-5p-mediated
posttranscriptional suppression of PCAF in PCa cells.
Indeed, we detected a decreased level of miR-17-5p in
PCa cell lines. Although a decrease in miR-17-5p expres-
sion can partially explain the upregulation of PCAF in
PCa cells through a relief of miR-17-5p-mediated post-
transcriptional suppression, the majority of previous
miRNA arrays done by different laboratories on prostate
tumors revealed an increase in miR-17-5p expression
[18,19]. Interestingly, expression of miR-17-3p, which is
from the 5’ arm of the precursor for miR-17-5p, appears
to be downregulated in prostate tumor tissue [20]. Ob-
viously, alterations in the expression profile of miR-17
cluster miRNAs in PCa cells differ in vivo and in vitro,
relevant to further studies on the role of miR-17 cluster
in prostate tumorigenesis. In addition, this study does
not preclude the possibility that other miRNAs maytarget PCAF in PCa cells, particularly, those miRNAs
that are downregulated in PCa cells. Moreover, the ques-
tion of whether the high level of PCAF protein detected
in PCa cells involves dysfunction in protein degradation
pathways merits further investigation.Conclusions
In this study, we demonstrated that PCAF is upregulated
in human PCa cell lines. PCAF acts as a co-activator for
AR, and promoter recruitment of PCAF enhances trans-
activation of AR-regulated genes in PCa cells. Upregula-
tion of PCAF in cultured PCa cells may be associated
with downregulation of miR-17-5p, a miRNA that sup-
presses PCAF mRNA translation and induces its degra-
dation. Therefore, miR-17-5p targets PCAF in cultured
PCa cells and modulates AR-regulated transcriptional
activity and PCa growth.
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